WILMINGTON, Mass., Oct. 31, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it will exhibit its QS-B220 desktop explosives and drugs trace detectors at Air Cargo Americas on November 6th through 8th in Miami, Florida at booth #929.
Implant Sciences' QS-B220 has recently been added to the "Qualified" section of the Air Cargo Screening Technology List (ACSTL), joining the list of products from which the TSA encourages regulated customers to purchase. Carriers and freight forwarders now have the option of deploying a screening technology that is free from radioactive materials and emits no ionizing radiation.
Only equipment listed on the ACSTL can be used for screening cargo carried on passenger planes landing or taking off from American airports. Additionally, many other countries accept TSA qualification when making purchase decisions.
"Air Cargo Americas is a great venue for us to highlight our QS-B220. Our system is recognized in the air cargo screening field as the new standard in trace detection," stated Todd Swearingen, General Manager, Americas for Implant Sciences. "A number of prospective buyers have heard from our current users that the QS-B220 is technologically superior to the competition. We look forward to demonstrating the product's competitive advantages to buyers throughout the Americas."
"This is a critical and exciting time for Implant Sciences. The QS-B220 has achieved a string of regulatory successes so far this year, and our systems have built a reputation for being easy-to-use and low-cost to maintain. We believe that an investment in trade shows and exhibitions this fall will help us capitalize on this momentum and increase our market share," stated Implant Sciences' President and CEO, Glenn D. Bolduc.
The 2011, Air Cargo Americas International Congress and Exhibition was the largest air cargo exhibition in the Western Hemisphere, with 6,903 international aviation and maritime business executives from 65 countries visiting the exhibition. According to Air Cargo Americas, at the Air Cargo & Sea Cargo Americas 2011 exhibition, more than $101 million in actual and projected sales were reported by exhibitors.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In October 2013, the Company became the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation